Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular scholarly challenges following the Russian invasion of Ukraine.
Biondi-Zoccai G, Pirlamarla P, Sabouret P, Kozhukhov S, Marchenko O, Hill JA, Mamas MA. Biondi-Zoccai G, et al. Among authors: sabouret p. Minerva Cardiol Angiol. 2022 Oct;70(5):525-528. doi: 10.23736/S2724-5683.22.06102-6. Epub 2022 Mar 28. Minerva Cardiol Angiol. 2022. PMID: 35343175 Free article. No abstract available.
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr, Bénezet JF, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E; ATOLL Investigators. Montalescot G, et al. Lancet. 2011 Aug 20;378(9792):693-703. doi: 10.1016/S0140-6736(11)60876-3. Lancet. 2011. PMID: 21856483 Clinical Trial.
A consensus statement on lipid management after acute coronary syndrome.
Schiele F, Farnier M, Krempf M, Bruckert E, Ferrières J; French Group. Schiele F, et al. Eur Heart J Acute Cardiovasc Care. 2018 Sep;7(6):532-543. doi: 10.1177/2048872616679791. Epub 2016 Nov 17. Eur Heart J Acute Cardiovasc Care. 2018. PMID: 27856518 Review.
How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators.
Sabouret P, Angoulvant D, Pathak A, Fysekidis M, Laterra G, Costa F, Angelini F, Bocchino PP, Montalescot G, Biondi-Zoccai G. Sabouret P, et al. Panminerva Med. 2022 Jun;64(2):265-273. doi: 10.23736/S0031-0808.21.04284-1. Epub 2021 Jun 1. Panminerva Med. 2022. PMID: 34060278 Review.
Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P, Bocchino PP, Angelini F, D'Ascenzo F, Galati G, Fysekidis M, DE Ferrari GM, Fischman DL, Bhatt DL, Biondi-Zoccai G. Sabouret P, et al. Minerva Cardiol Angiol. 2023 Apr;71(2):199-207. doi: 10.23736/S2724-5683.22.05900-2. Epub 2022 Feb 23. Minerva Cardiol Angiol. 2023. PMID: 35195376 Free article.
88 results